As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.
Direct-purchase agreements are being floated as a price-control strategy. But how is value defined? And when might low cost come at the expense of true value?
The election results sent biopharma stock soaring. Breaking down what’s really on tap for biopharma over the next four years.
Navigating the new checks-and-balances world of value-based pricing.
How a progressive GlaxoSmithKline (GSK) is leading the way in offering game-changing value-based pricing.
The Deal features David Campbell on how healthcare companies can leverage royalties, not their balance sheets, to fund innovation.
Our Health & Life Sciences team returned from this year's annual JP Morgan Healthcare Conference in San Francisco with discussions around partnerships and consumerism particularly reverberating.
Duke Royalty Limited, a Guernsey-based public diversified royalty company, and Oliver Wyman announced this week a financing collaboration in the rapidly developing pharmaceutical and healthcare-related royalty market.
Last week Reuters reported that Novartis plans to use a novel pricing model when it launches its new heart failure drug Entresto. David Campbell, an Oliver Wyman Partner who specializes in valuing new drugs, breaks down how this new model could impact the traditional pharma-payer-provider dynamic.